AMAG PHARMACEUTICALS, INC. short interest in 2020
In 2020, AMAG PHARMACEUTICALS, INC.'s disclosed short interest ran from 43.18% of shares outstanding on 15 Jan 2020 to 10.82% on 13 Nov 2020, a change of -32.36 percentage points. The year's high was 43.18% on 15 Jan 2020 and its low 10.82% on 13 Nov 2020, averaging 32.58% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 36.72 days on 31 Aug 2020. Full history: AMAG PHARMACEUTICALS, INC..
Cite this page
2020 in figures
- Start of year
- 43.18% (15 Jan 2020)
- End of year
- 10.82% (13 Nov 2020)
- Change
- -32.36 pp
- High
- 43.18% (15 Jan 2020)
- Low
- 10.82% (13 Nov 2020)
- Average
- 32.58%
- Highest days to cover
- 36.72 (31 Aug 2020)
- SEC filings marked
- 8
Every report in 2020
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2020 | 43.18% | 17.41 | results (8-K) |
| 31 Jan 2020 | 40.65% | 9.69 | |
| 14 Feb 2020 | 38.07% | 31.66 | |
| 28 Feb 2020 | 37.17% | 18.36 | |
| 13 Mar 2020 | 35.28% | 15.22 | results (8-K), 10-K filed |
| 31 Mar 2020 | 34.65% | 18.03 | |
| 15 Apr 2020 | 35.25% | 26.28 | |
| 30 Apr 2020 | 35.82% | 26.53 | |
| 15 May 2020 | 36.54% | 19.78 | 10-Q filed, results (8-K) |
| 29 May 2020 | 36.05% | 29.80 | |
| 15 Jun 2020 | 36.44% | 29.32 | |
| 30 Jun 2020 | 35.95% | 17.06 | |
| 15 Jul 2020 | 34.90% | 34.15 | |
| 31 Jul 2020 | 32.77% | 23.17 | |
| 14 Aug 2020 | 31.55% | 24.84 | results (8-K) |
| 31 Aug 2020 | 30.94% | 36.72 | 10-Q filed |
| 15 Sep 2020 | 29.47% | 24.36 | |
| 30 Sep 2020 | 29.41% | 25.47 | |
| 15 Oct 2020 | 20.96% | 1.29 | |
| 30 Oct 2020 | 18.24% | 6.27 | |
| 13 Nov 2020 | 10.82% | 2.55 | 10-Q filed |
See also: AMAG PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2020 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.